Dr. Jens Göpfert

Jens Göpfert is a Senior Principal Scientist at the NMI and is responsible for the development and validation of modern immunological assays, ranging from established methods to ultra-sensitive technologies such as Simoa. His work and that of his team focuses on biomarker strategies, robust assay platforms, and reliable data to support preclinical and clinical development. This includes the production and characterization of assay reagents, the implementation of GCP compliant assays, and the execution of exploratory and clinical study sample analyses. In addition, he advises internal and external partners on technology selection and biomarker driven project strategies.

Selected publications

• Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor. Bioanalysis, 2019, DOI: 10.4155/bio-2019
• Serum interferon-a measured by single-molecule array associates with systemic disease manifestations in Sjögren’s syndrome. Rheumatology, 2021, DOI: 10.1093/688
• A generic operational strategy to qualify translational safety biomarkers. Drug Discovery Today, 2011, DOI: 10.16600-608
• Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia. Nature Communications, 2022, DOI: 10.106427
• Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight, 2022, DOI: 10.1172/t.154395

ORCID: https://orcid.org/0000-0003-3525-3684